LCA Immunohistochemistry at Lahore PCR Lab

LCA Immunohistochemistry at Lahore PCR Lab

LCA (Leukocyte Common Antigen) Immunohistochemistry, also scientifically designated as CD45 immunohistochemical staining, is a highly specialized and indispensable diagnostic pathology test performed at Lahore PCR Lab in Lahore, Pakistan. This advanced diagnostic technique is utilized by consultant pathologists to identify cells of hematopoietic and lymphoid origin within tissue specimens. By employing highly specific monoclonal antibodies that bind directly to the CD45 cell-surface glycoprotein, this test allows for the precise differentiation of hematolymphoid malignancies, such as lymphomas and leukemias, from non-hematopoietic neoplasms like carcinomas, melanomas, and sarcomas. The clinical utility of this test is paramount in oncological diagnostics, where determining the exact lineage of an undifferentiated tumor is the critical first step toward formulating an effective, targeted therapeutic regimen.

At Lahore PCR Lab, the LCA Immunohistochemistry test is executed using state-of-the-art automated staining platforms and high-affinity antibodies, ensuring maximum sensitivity and specificity. The process begins with a tissue biopsy or surgical resection specimen, which is meticulously processed, embedded in paraffin, and sectioned into ultra-thin slices. These slices are then subjected to antigen retrieval protocols, incubated with primary anti-CD45 antibodies, and visualized using advanced chromogenic detection systems under high-resolution light microscopy. The anatomical structures evaluated depend entirely on the biopsy site, which frequently includes lymph nodes, bone marrow, spleen, mediastinal masses, retroperitoneal tissues, or any solid organ harboring an undifferentiated tumor. The diagnostic value of LCA IHC lies in its ability to provide clear, objective, and reproducible cellular identification, transforming ambiguous histopathological features into definitive diagnostic classifications that guide oncologists, hematologists, and surgeons in Lahore and across Pakistan.

Clinical Procedure: What to Expect

Patient Preparation

Because LCA Immunohistochemistry is performed directly on a tissue specimen (biopsy or surgical resection sample) rather than a direct blood draw, patient preparation is primarily focused on the surgical or interventional procedure required to obtain the tissue. If you are submitting an existing formalin-fixed paraffin-embedded (FFPE) tissue block or pre-cut slides from another facility to Lahore PCR Lab, no direct patient preparation is necessary. However, if you are undergoing a biopsy at an affiliated clinical site, please adhere to the following guidelines:

• Medication Review: Inform your referring physician and the clinical staff of all medications you are currently taking, particularly blood thinners (such as aspirin, clopidogrel, warfarin, or direct oral anticoagulants) which may need to be temporarily discontinued prior to a biopsy.
• Fasting Requirements: If your biopsy requires local anesthesia with sedation or general anesthesia (such as an excisional lymph node biopsy or deep core needle biopsy), you will be instructed to fast (no food or liquids) for 6 to 8 hours before the procedure.
• Hygiene and Clothing: Wear loose, comfortable clothing on the day of the biopsy. Ensure the biopsy site is clean and free of lotions, powders, or perfumes.
• Medical History Documentation: Bring all relevant medical records, previous pathology reports, and imaging studies (such as CT scans or ultrasounds) to Lahore PCR Lab to assist the consultant pathologists in their clinical correlation.
• Post-Procedure Care: Arrange for a family member or friend to drive you home if your biopsy procedure involves sedation. Follow all post-biopsy wound care instructions provided by your physician to prevent infection.

During the Procedure

The laboratory phase of LCA Immunohistochemistry at Lahore PCR Lab is a highly controlled, multi-step analytical process conducted by skilled histotechnologists and evaluated by consultant pathologists:

• Specimen Reception and Accessioning: The tissue specimen, preserved in 10% neutral buffered formalin, is received at the laboratory, assigned a unique tracking barcode, and matched with the patient’s clinical history.
• Tissue Processing and Embedding: The tissue undergoes dehydration, clearing, and infiltration with paraffin wax. It is then embedded into a solid paraffin block, which preserves the cellular architecture indefinitely.
• Microtomy: A highly precise instrument called a microtome is used to cut the paraffin block into extremely thin sections, typically 3 to 5 microns thick. These sections are carefully floated onto glass microscope slides.
• Deparaffinization and Rehydration: The slides are heated and treated with organic solvents (such as xylene) and descending grades of alcohol to remove the paraffin wax and rehydrate the tissue sections.
• Antigen Retrieval: To expose the CD45 epitopes that may have been masked during formalin fixation, the slides are subjected to heat-induced epitope retrieval (HIER) using specialized buffer solutions in a temperature-controlled environment.
• Antibody Incubation: The tissue sections are incubated with a highly specific primary monoclonal antibody directed against the Leukocyte Common Antigen (CD45). This is followed by the application of a secondary antibody conjugated to an enzyme complex (such as horseradish peroxidase).
• Chromogen Visualization: A chromogenic substrate, typically diaminobenzidine (DAB), is applied to the slides. The enzyme reaction precipitates a visible brown pigment at the site of antigen-antibody binding, marking LCA-positive cells.
• Counterstaining and Mounting: The slides are counterstained with hematoxylin to provide cellular contrast (staining cell nuclei blue), dehydrated, and sealed with a coverslip for permanent preservation.
• Microscopic Analysis: A consultant pathologist examines the stained slides under a high-power light microscope, assessing the staining intensity, cellular localization (membranous), and distribution of the positive cells.

When is a LCA Immunohistochemistry Performed?

Differentiating Carcinoma from Lymphoma

One of the most common and critical indications for LCA Immunohistochemistry is the evaluation of highly undifferentiated malignant tumors. Under standard hematoxylin and eosin (H&E) staining, anaplastic carcinomas and large cell lymphomas can look virtually identical, presenting as sheets of large, atypical cells. Because the treatment pathways for carcinoma (chemotherapy, radiation, surgery) and lymphoma (systemic immunotherapy, specific chemotherapy protocols) are vastly different, an accurate distinction is vital. A positive LCA stain confirms a hematolymphoid origin, pointing toward lymphoma, while a negative LCA stain in an undifferentiated tumor strongly suggests a non-lymphoid malignancy like carcinoma.

Evaluation of Lymphadenopathy

Persistent, unexplained lymphadenopathy (swollen lymph nodes) is a primary clinical symptom that warrants a biopsy and subsequent immunohistochemical analysis. When a patient presents with localized or generalized lymph node enlargement, a biopsy is performed to rule out malignancy. LCA IHC is used to evaluate the architecture of the lymph node, confirming whether the proliferating cell population consists of normal, reactive lymphocytes (which will be LCA positive in a structured pattern) or a clonal, neoplastic expansion characteristic of non-Hodgkin or Hodgkin lymphoma.

Investigating Undifferentiated Malignant Neoplasms

In cases where a patient presents with a metastatic tumor of unknown primary origin, the tumor cells are often highly undifferentiated, having lost their normal tissue characteristics. Physicians request a broad immunohistochemical panel, with LCA as a foundational marker, to categorize the tumor into a broad lineage (epithelial, mesenchymal, melanocytic, or hematopoietic). This initial categorization prevents diagnostic errors and directs subsequent, more specific antibody testing to pinpoint the exact tumor type and origin.

Staging and Subtyping Hematolymphoid Malignancies

Once a tumor is identified as hematolymphoid in origin via LCA positivity, pathologists use LCA IHC in conjunction with a panel of other lineage-specific markers (such as CD3 for T-cells, CD20 for B-cells, CD30, and CD15) to subtype the malignancy. This is crucial for distinguishing between various forms of Non-Hodgkin Lymphoma, Hodgkin Lymphoma, and leukemia presenting as solid masses (granulocytic sarcoma). Accurate subtyping is essential for determining the prognosis and selecting the most effective targeted therapies.

Monitoring Unexplained Systemic Symptoms (B-Symptoms)

Patients presenting with unexplained systemic symptoms, collectively known as “B-symptoms”—including drenching night sweats, recurrent high fevers, and significant unintentional weight loss—often undergo diagnostic imaging that reveals deep-seated masses or organomegaly. When these masses are biopsied, LCA Immunohistochemistry is routinely performed to investigate the possibility of an underlying systemic hematologic malignancy, providing the definitive diagnostic evidence required to initiate life-saving hematological treatments.

What Does a LCA Immunohistochemistry Detect?

LCA Immunohistochemistry is designed to detect the presence and distribution of the CD45 glycoprotein on cell membranes. The diagnostic findings from this test provide critical insights into the nature of the tissue specimen:

• Hematopoietic Lineage Confirmation: Strong, diffuse membranous staining across the tumor cell population confirms that the neoplasm is of hematopoietic or lymphoid origin.
• Exclusion of Non-Lymphoid Malignancies: A completely negative LCA stain in tumor cells effectively rules out most lymphomas and leukemias, redirecting the diagnostic focus toward carcinomas, sarcomas, or melanomas.
• Identification of Inflammatory Infiltrates: In non-neoplastic, inflammatory, or infectious conditions, LCA IHC highlights the presence, density, and distribution of reactive inflammatory cells (T-lymphocytes, B-lymphocytes, histiocytes) within the tissue.
• Detection of Hodgkin Lymphoma Characteristics: In classic Hodgkin Lymphoma, the neoplastic Reed-Sternberg cells are typically negative for LCA (CD45), whereas the surrounding background of reactive lymphocytes is strongly positive. This characteristic discordant staining pattern is highly diagnostic.
• Delineation of Tumor Margins: LCA IHC can help pathologists identify microscopic infiltration of lymphoma cells into surrounding normal tissues, assisting in accurate tumor staging.
• Characterization of Bone Marrow Infiltration: When applied to bone marrow trephine biopsies, LCA staining helps detect and quantify the extent of involvement by leukemic or lymphomatous cells.
• Differentiation of Small Round Blue Cell Tumors: In pediatric and young adult patients, tumors presenting as “small round blue cells” (such as neuroblastoma, rhabdomyosarcoma, Ewing sarcoma, and lymphoblastic lymphoma) are notoriously difficult to distinguish. LCA positivity specifically isolates lymphoblastic lymphoma from the other options.
• Identification of Histiocytic and Dendritic Cell Neoplasms: These rare tumors of the hematopoietic system typically retain LCA expression, aiding in their differentiation from soft tissue sarcomas.

Turnaround Time and Report Access at Lahore PCR Lab

At Lahore PCR Lab, we understand that waiting for pathology results can be an anxious time for patients and their families, especially when a diagnosis of malignancy is suspected. Because immunohistochemistry requires meticulous tissue processing, antigen retrieval, multiple incubation steps, and expert microscopic evaluation, the turnaround time for LCA Immunohistochemistry is typically 3 to 5 working days from the receipt of the specimen or paraffin block. This timeframe ensures that every step of the complex staining process is executed to the highest standards of quality control and that the slides are thoroughly reviewed by our consultant pathologists.

Once the diagnostic report is finalized and signed off by the consultant pathologist, patients and referring physicians are immediately notified via SMS. Lahore PCR Lab provides secure, convenient digital access to reports through our official online portal. Patients can view, download, and print their high-resolution PDF reports from the comfort of their homes. Additionally, physical copies of the reports can be collected directly from our main facility in Lahore or any of our designated collection centers. Our reports include detailed microscopic descriptions, high-quality digital photomicrographs of the stained slides when applicable, and a comprehensive clinical correlation to assist your oncologist in planning your treatment.

LCA Immunohistochemistry Findings Overview

The following table outlines the typical diagnostic findings and interpretations associated with LCA (CD45) Immunohistochemistry in various tissue contexts:

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Lymphoid Tissue (e.g., Lymph Node)	Strong, organized membranous positivity in B and T lymphocytes within lymphoid follicles and paracortex.	Disrupted architecture with diffuse, monoclonal sheets of strongly LCA-positive atypical cells (suggestive of Non-Hodgkin Lymphoma).
Undifferentiated Epithelial Tumors	LCA negative; normal resident lymphocytes in the background may show positivity.	Tumor cells are completely LCA negative, but positive for epithelial markers like Cytokeratins (confirms Carcinoma).
Classic Hodgkin Lymphoma	Not applicable (reactive lymph node shows normal LCA distribution).	Large, atypical Reed-Sternberg cells are LCA negative, surrounded by a dense background of LCA-positive reactive T-cells.
Small Round Blue Cell Tumors	Negative in non-hematopoietic tissues.	Strong LCA positivity confirms Lymphoblastic Lymphoma, distinguishing it from LCA-negative Ewing Sarcoma or Neuroblastoma.
Bone Marrow Trephine Biopsy	Normal distribution of hematopoietic cells showing variable LCA positivity based on cell maturity.	Hypercellular marrow packed with sheets of strongly LCA-positive immature blasts (suggestive of Leukemia or Myeloma involvement).
Mesenchymal Tumors (Sarcomas)	LCA negative in stromal and connective tissue cells.	Tumor cells are LCA negative, but positive for mesenchymal markers like Vimentin or Desmin (rules out lymphoma).
Inflammatory Lesions	Scattered, normal inflammatory cells showing LCA positivity.	Dense, polyclonal infiltration of LCA-positive inflammatory cells without cytological atypia (indicates chronic inflammation or infection).

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Lahore PCR Lab for LCA Immunohistochemistry?

• Experienced Healthcare Professionals: Our pathology department is led by highly qualified consultant pathologists with specialized training in histopathology and immunohistochemistry.
• Patient-Focused Care: We prioritize patient well-being, ensuring that all specimens are handled with the utmost care, respect, and clinical urgency.
• Quality Diagnostic Services: Lahore PCR Lab adheres to strict international quality control standards, ensuring highly reproducible and clinically reliable staining results.
• Professional Reporting: Our diagnostic reports are comprehensive, detailed, and structured to provide referring oncologists with clear, actionable diagnostic information.
• Modern Diagnostic Approach: We utilize advanced automated IHC staining systems that minimize human error and optimize antibody-antigen binding specificity.
• Comfortable Environment: Our collection centers and main facility in Lahore offer a clean, professional, and welcoming environment for patients submitting samples.
• Convenient Location: Strategically located in Lahore, our laboratory is easily accessible for patients, hospitals, and clinics across the city and surrounding regions.
• Commitment to Accurate Diagnosis: We are dedicated to providing the highest level of diagnostic accuracy, helping patients receive the correct diagnosis and timely treatment.